Kodiak Sciences Announces Positive Phase 3 GLOW2 Results for Zenkuda in Diabetic Retinopathy, Accelerating BLA Submission

summarizeSummary

Kodiak Sciences announced positive Phase 3 results for Zenkuda in diabetic retinopathy, showing superiority over sham and leading to an accelerated BLA submission timeline.

check_boxKey Events

• Positive Phase 3 GLOW2 Results

  Zenkuda (tarcocimab tedromer) demonstrated superiority over sham in the GLOW2 Phase 3 study for diabetic retinopathy.

• Significant Efficacy Achieved

  62.5% of Zenkuda-treated patients achieved a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p<0.0001).

• Reduced Sight-Threatening Complications

  Zenkuda reduced the risk of developing sight-threatening complications by 85% compared to sham.

• Favorable Safety Profile

  The drug was well-tolerated with a 0% intraocular inflammation rate and low cataract adverse event rates.

auto_awesomeAnalysis

Kodiak Sciences reported highly positive topline results from its GLOW2 Phase 3 study for Zenkuda (tarcocimab tedromer) in diabetic retinopathy. The study demonstrated Zenkuda's superiority over sham with strong statistical significance in improving diabetic retinopathy severity and reducing sight-threatening complications. This successful outcome, coupled with a favorable safety profile, provides Zenkuda with a multi-indication BLA-ready profile, prompting the company to accelerate its Biologics License Application submission plans. This is a critical de-risking event for Kodiak, validating its proprietary ABC Platform and significantly advancing its lead product candidate towards commercialization, which could be a major catalyst for future revenue growth.